FDA Congressional Relations, Internal Structure May Change With Sharfstein Exit
This article was originally published in The Tan Sheet
Executive Summary
The departure of Principal Deputy Commissioner Josh Sharfstein provides FDA an opportunity to take stock of its relationship with Congress and to re-evaluate its organizational structure.
You may also be interested in...
Woodcock To Be Acting US FDA Commissioner; Sharfstein Tops Biden's List Of Candidates For Post
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
Woodcock To Be Acting US FDA Commissioner, Leaving Agency in Stable, Capable Hands
Agency has been prepping Woodcock for the temporary task but what will happen to her role on Operation Warp Speed remains unclear. The move should give Biden team cushion to confirm a permanent leader of whom a top contender is former senior FDA staffer Joshua Sharfstein, a proponent of drug reforms that may irk manufacturers.
FDA Becomes An Agency Of “Directorates” Under Hamburg’s Reorganization
Commissioner Margaret Hamburg’s structural reorganization of FDA leaves the current leadership of the agency’s centers intact, but adds a new layer of management and accountability between the medical product center directors and the commissioner’s office.